To The Administration
HLC letter expressing concerns over proposals to limit intellectual property protections for COVID-19 diagnostic tools and therapeutics under the World Trade Organization’s TRIPS agreement.
- Topics: Competition, Innovation, Medicare
Related Letters & Comments
HLC drives policy change through strategic letters, comments, and reports that promote private-sector innovation. Focused on priorities like Medicare reform, telehealth, and health equity, HLC engages with lawmakers and agencies to shape a smarter, more responsive healthcare system.
To The Administration
HLC comments support strengthening intellectual property provisions of USMACA
To The Administration
HLC response to the Federal Trade Commission’s RFI regarding noncompete agreements
To Congress
